ARRY Surges 37% Into Earnings as Options Flip and Shorts Retreat

Array Technologies posted a 37% gain on the week into its November 5 earnings print, and the positioning picture shifted materially from the one described in last week's note.

The most striking change is in options. The put/call ratio has jumped to 0.55, nearly three standard deviations above its 20-day mean of 0.21, and a world away from the 0.15 reading flagged a week ago. That was the 52-week low; this is the most defensive the options market has been in months. The PCR hit 0.56 on November 2 as well, confirming this is not noise. In the previous note, options traders appeared indifferent to the bearish short positioning; they are no longer. Heading into results, they are buying protection at the fastest pace of the year.

Short interest eased slightly on the week but remains deeply elevated. The latest ORTEX daily estimate puts shares short at 41 million, or 26.9% of free float, up 4% on the week and up 13% over the past month. Availability remains locked at zero: every share in the lending pool is out on loan, matching the 52-week floor. The cost to borrow at 0.88% has barely moved, the same paradox noted last week. The borrow market is at maximum tightness but borrow costs have not reflected any squeeze pressure, suggesting the short book is settled rather than stressed. With 27% of float short and a 22% single-day rally into the print, any continued upward move puts that positioning under real pressure.

The Street has been uniformly cutting targets in the run-up. Guggenheim slashed its price target from $13 to $6 on October 28 while holding its Buy rating, the most dramatic cut of the cycle. JPMorgan, Morgan Stanley, Barclays, and Mizuho all lowered targets in the two weeks prior. The mean target now sits at $6.94 against a close of $4.64, implying roughly 50% upside on paper, though the consensus direction has been firmly downward. Mizuho was the lone dissenter on direction, upgrading to Outperform from Neutral on October 15, even as it cut its target. The bull case centres on a strong booking backdrop, with LTM bookings of $1.89 billion and a 1.5x trailing book-to-bill, plus the OmniTrack and APA Solar product expansion. Bears focus on the $325 million convertible due December 2028 and a preferred dividend that grows to 10.25% by mid-2031, risks that cut available cash flow and raise the spectre of dilutive refinancing. The EV/EBITDA multiple has drifted up to 6.7x on the week's move, while the earnings yield factor ranks in the 78th percentile, a signal the stock looks statistically cheap even after the rally.

The index deletion overhang has not gone away. ORTEX forecasts an 87% probability of removal from the CRSP US Small index at the December 2026 Quarterly Review, which would force roughly $10 million of passive selling around December 22. For the MSCI USA IMI, USA Small, World IMI and World Small indices, ORTEX puts the deletion probability at 67%, with the announcement due November 11 and trade date November 30. That is $26 million to $46 million of mechanically forced selling across those reviews combined. The price that decides the MSCI outcome is $5.78; the stock closed at $4.64, leaving it 24.6% below that threshold. Passive selling pressure is therefore a live risk in both November and December regardless of how earnings land.

Peers moved sharply with ARRY this week. NXT gained 21% on the week and RUN added 15%, while SHLS rose 13%. The correlated move suggests sector-wide relief rather than a company-specific catalyst, which makes the earnings print tomorrow evening a more precise test of whether ARRY's underlying fundamentals justify the rally or whether the week's gain was simply beta.

The November 5 print is the clearest near-term catalyst, but the November 11 MSCI announcement and the December CRSP review are the structural forces that will shape positioning for the rest of the quarter regardless of the quarterly result.